BOLD asynchrony: An imaging biomarker of tumor burden in IDH-mutated gliomas

Neuro Oncol. 2022 Jan 5;24(1):88-89. doi: 10.1093/neuonc/noab248.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Biomarkers
  • Glioma* / genetics
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Tumor Burden

Substances

  • Biomarkers
  • Isocitrate Dehydrogenase